New Zealand markets open in 20 minutes

C4 Therapeutics, Inc. (CCCC)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
6.43-0.11 (-1.68%)
At close: 04:00PM EDT
6.40 -0.03 (-0.47%)
After hours: 05:05PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 448.65M
Enterprise value 265.94M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)15.64
Price/book (mrq)1.82
Enterprise value/revenue 12.81
Enterprise value/EBITDA -2.08

Trading information

Stock price history

Beta (5Y monthly) 3.19
52-week change 3102.48%
S&P500 52-week change 323.57%
52-week high 311.88
52-week low 31.06
50-day moving average 38.40
200-day moving average 34.69

Share statistics

Avg vol (3-month) 32.31M
Avg vol (10-day) 31.18M
Shares outstanding 568.6M
Implied shares outstanding 668.6M
Float 852.5M
% held by insiders 111.59%
% held by institutions 176.16%
Shares short (15 Apr 2024) 49.56M
Short ratio (15 Apr 2024) 44.55
Short % of float (15 Apr 2024) 419.77%
Short % of shares outstanding (15 Apr 2024) 413.94%
Shares short (prior month 15 Mar 2024) 45.29M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-1,147.71%

Management effectiveness

Return on assets (ttm)-21.53%
Return on equity (ttm)-49.50%

Income statement

Revenue (ttm)20.76M
Revenue per share (ttm)0.42
Quarterly revenue growth (yoy)14.30%
Gross profit (ttm)N/A
EBITDA -137.15M
Net income avi to common (ttm)-132.49M
Diluted EPS (ttm)-2.67
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)253.68M
Total cash per share (mrq)3.7
Total debt (mrq)70.98M
Total debt/equity (mrq)28.84%
Current ratio (mrq)6.34
Book value per share (mrq)4.07

Cash flow statement

Operating cash flow (ttm)-106.84M
Levered free cash flow (ttm)-66.06M